Nataša Mitrović

Dr. Nataša Mitrović

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2013 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
Dunja DrakulićDunja Drakulić
Dunja Drakulić
NVNataša Veličković
Nataša Veličković
MSMilos Stanojlovic
Milos Stanojlovic
IGIvana Grković
Ivana Grković
NMNataša Mitrović
Nataša Mitrović
AHA. Horvat
A. Horvat

22 February 2014 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
IGIvana Grković
Ivana Grković
IBIvana Bjelobaba
Ivana Bjelobaba
NNNadezda Nedeljkovic
Nadezda Nedeljkovic
NMNataša Mitrović
Nataša Mitrović
Dunja DrakulićDunja Drakulić
Dunja Drakulić
AHAnica Horvat
Anica Horvat

1 December 2019 in Neuroscience
Verified
Journal Article
Closed access
Milorad DragicMilorad Dragic
Milorad Dragic
Marina Zaric KonticMarina Zaric Kontic
Marina Zaric Kontic
NMNataša Mitrović
Nataša Mitrović
NNNadežda Nedeljković
Nadežda Nedeljković
IGIvana Grković
Ivana Grković

6 July 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
IGIvana Grković
Ivana Grković
NMNataša Mitrović
Nataša Mitrović
Milorad DragicMilorad Dragic
Milorad Dragic
MAMarija Adžić
Marija Adžić
Dunja DrakulićDunja Drakulić
Dunja Drakulić
NNNadežda Nedeljković
Nadežda Nedeljković


21 February 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Marina Zaric KonticMarina Zaric Kontic
Marina Zaric Kontic
Milorad DragicMilorad Dragic
Milorad Dragic
Jelena MartinovicJelena Martinovic
Jelena Martinovic
KMKatarina Mihajlovic
Katarina Mihajlovic
ZBZeljka Brkic
Zeljka Brkic
IGIvana Grković
Ivana Grković
Alprazolam (ALP), a benzodiazepine (BDZ) used to treat anxiety, panic, and sleep disorders, is one of the most prescribed psychotropic drugs worldwide. The side effects associated with long-term (mis)use of ALP have become a major challenge in pharmacotherapy, emphasizing the unmet need to further investigate their underlying molecular mechanisms. Prolonged BDZ exposure may induce adaptive changes in the function of several receptors, including the primary target, gammaaminobutyric acid receptor type A (GABAAR), but also other neurotransmitter receptors such as glutamatergic. The present study investigated the potential effects of prolonged ALP treatment on components of glutamatergic neurotransmission, with special emphasis on N-Methyl-D-aspartate receptor (NMDAR) in the hippocampus of adult male Wistar rats. The study revealed behavioral changes consistent with potential onset of tolerance and involvement of the glutamatergic system in its development. Specifically, an increase in NMDAR subunits (NR1, NR2A, NR2B), a decrease in vesicular glutamate transporter 1 (vGlut1), and differential modulation of excitatory amino acid transporters 1 and 2 (EAAT1/2, in vivo and in vitro) were observed, alongside a decrease in α1-containing GABAAR following the treatment. By describing the development of compensatory actions in the glutamatergic system, the present study provides valuable information on neuroadaptive mechanisms following prolonged ALP intake.